Die kostenlosen ARIVA.DE Börsen-Dienste:
Bleiben Sie immer informiert und melden Sie sich jetzt für die Newsletter von ARIVA.DE an!
Jetzt kostenlos abonnieren

Trader 2017/6: Kwasimodo

Cashbestand:
131.207,00 €
Platz:
Gesamtwert mit Cash:
270.645,00 € (28.04.20 11:23)
Börsenspiel beendet. Diese Werte werden nicht mehr aktualisiert.
Kurse zum Spielende    

News

Zeit
Titel
Wertpapier
 
Fr Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
Moleculin Biotech Inc
Mi Moleculin to Present at the Virtual Investor Pitch Conference
Moleculin Biotech Inc
05.06.24 Moleculin to Participate in the Virtual Investor Lunch Break Series
Moleculin Biotech Inc
16.05.24 Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Moleculin Biotech Inc
15.05.24 Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
Moleculin Biotech Inc
13.05.24 Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
Moleculin Biotech Inc
09.05.24 Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Moleculin Biotech Inc
08.05.24 Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
Moleculin Biotech Inc
07.05.24 Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Moleculin Biotech Inc
02.05.24 Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Moleculin Biotech Inc
01.05.24 Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Moleculin Biotech Inc
18.04.24 European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech Inc
10.04.24 Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Moleculin Biotech Inc
28.03.24 Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Moleculin Biotech Inc
27.03.24 Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
Moleculin Biotech Inc
27.03.24 Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Moleculin Biotech Inc
25.03.24 Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Moleculin Biotech Inc
22.03.24 Moleculin Reports Full Year 2023 Financial Results
Moleculin Biotech Inc
20.03.24 Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
Moleculin Biotech Inc
19.03.24 Moleculin Announces Reverse Stock Split
Moleculin Biotech Inc
12.03.24 Moleculin to Present at the 36th Annual ROTH Conference
Moleculin Biotech Inc
24.01.24 Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Moleculin Biotech Inc
20.12.23 Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
Moleculin Biotech Inc
11.12.23 Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
Moleculin Biotech Inc
13.11.23 Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
Moleculin Biotech Inc
13.11.23 Moleculin Reports Third Quarter 2023 Financial Results
Moleculin Biotech Inc
07.11.23 Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
Moleculin Biotech Inc
06.11.23 Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
Moleculin Biotech Inc
11.10.23 Moleculin to Participate in the Virtual Investor Ask the CEO Conference
Moleculin Biotech Inc
02.10.23 Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech Inc
Fr
Moleculin Biotech Inc
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
Mi
Moleculin Biotech Inc
Moleculin to Present at the Virtual Investor Pitch Conference
05.06.24
Moleculin Biotech Inc
Moleculin to Participate in the Virtual Investor Lunch Break Series
16.05.24
Moleculin Biotech Inc
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
15.05.24
Moleculin Biotech Inc
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
13.05.24
Moleculin Biotech Inc
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
09.05.24
Moleculin Biotech Inc
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
08.05.24
Moleculin Biotech Inc
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
07.05.24
Moleculin Biotech Inc
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
02.05.24
Moleculin Biotech Inc
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
01.05.24
Moleculin Biotech Inc
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
18.04.24
Moleculin Biotech Inc
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
10.04.24
Moleculin Biotech Inc
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
28.03.24
Moleculin Biotech Inc
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
27.03.24
Moleculin Biotech Inc
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
27.03.24
Moleculin Biotech Inc
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
25.03.24
Moleculin Biotech Inc
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
22.03.24
Moleculin Biotech Inc
Moleculin Reports Full Year 2023 Financial Results
20.03.24
Moleculin Biotech Inc
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
19.03.24
Moleculin Biotech Inc
Moleculin Announces Reverse Stock Split
12.03.24
Moleculin Biotech Inc
Moleculin to Present at the 36th Annual ROTH Conference
24.01.24
Moleculin Biotech Inc
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
20.12.23
Moleculin Biotech Inc
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
11.12.23
Moleculin Biotech Inc
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
13.11.23
Moleculin Biotech Inc
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
13.11.23
Moleculin Biotech Inc
Moleculin Reports Third Quarter 2023 Financial Results
07.11.23
Moleculin Biotech Inc
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
06.11.23
Moleculin Biotech Inc
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
11.10.23
Moleculin Biotech Inc
Moleculin to Participate in the Virtual Investor Ask the CEO Conference
02.10.23
Moleculin Biotech Inc
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Musterdepot - © Ismagilov / Shutterstock

Das kostenlose Musterdepot von ARIVA.DE

Bei einem niedrigen Kurs einsteigen, bei einem hohen Kurs wieder verkaufen – es klingt einfach, an der Börse Erfolg zu haben. Tatsächlich brauchen Aktionäre gute Nerven, wenn die Kurse auf und ab schwanken. Realistische Anlageziele, eine klare Linie bei der Auswahl der Wertpapiere und das clevere Einsetzen bestimmter Ordertypen gehören zum Handwerk beim Handel mit Wertpapieren.

Um ein Gefühl dafür zu bekommen, welche Strategien in welchen Börsenphasen fruchten, können Nutzerinnen und Nutzer bei ARIVA.DE kostenlos ein Musterdepot anlegen und Wertpapiere wie Anleihen, Aktien, Derivate oder Fonds virtuell im Musterdepot handeln. Die Orders werden zum Schein ausgeführt und finden sich dann in einem virtuellen Musterdepot, ohne dass die Papiere tatsächlich ge- oder verkauft werden. So lassen sich Anlagestrategien testen, ohne Geld zu riskieren.

Viele Nutzer bauen auf ARIVA.DE im Musterdepot ihr reales Depot nach, das ein Broker für sie führt. Grund: Beim Musterdepot auf ARIVA.DE ist jede Position mit den zugehörigen News, dem Forum und der Profilseite verlinkt. Über die Aktien auf dem Laufenden zu bleiben, ist durch das Musterdepot sehr einfach. Möglich ist es auf ARIVA.DE auch, interessante Wertpapiere in eine Watchlist aufzunehmen, um ihre Entwicklung im Auge zu behalten. Nutzer können dabei Kursgrenzen vorgeben und sich bei Erreichen benachrichtigen lassen.

Übrigens: Wer ein virtuelles Musterdepot im Rahmen eines der Börsenspiele von ARIVA.DE eröffnet, hat einen weiteren Lerneffekt: Beim Börsenspiel wird ein Budget vorgegeben, und für jede Transaktion fallen virtuelle Gebühren an. Das macht den „Scheinhandel“ noch realistischer.